So one of the updates going to be presented today at the meeting, is in regards to talquetamab and dose modifications, suggesting that, you know, certainly the majority of patients end up with dose modifications because of some of the AEs. But the encouraging thing is, with those dose modifications, that patients can maintain responses and the further treatment-emergent AEs seem to come down...
So one of the updates going to be presented today at the meeting, is in regards to talquetamab and dose modifications, suggesting that, you know, certainly the majority of patients end up with dose modifications because of some of the AEs. But the encouraging thing is, with those dose modifications, that patients can maintain responses and the further treatment-emergent AEs seem to come down. So again, just suggesting management strategies, now that we do have taquetamab available to us commercially, in regards to optimizing response durations for these patients.